Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Enanta Pharmaceuticals ( (ENTA) ).
At its annual meeting on March 11, 2026, Enanta Pharmaceuticals’ shareholders re-elected Bruce L.A. Carter, Ph.D., and Jay R. Luly, Ph.D., as Class I directors to serve until the 2029 annual meeting, reinforcing continuity in the company’s board leadership. Stockholders also approved an amendment to the 2019 Equity Incentive Plan, adding 1.6 million shares for potential issuance, which may support employee retention and align management incentives with long-term shareholder interests.
Shareholders further passed an advisory “say-on-pay” resolution endorsing the compensation of Enanta’s named executive officers, signaling broad investor support for current pay practices and governance. In addition, investors ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending September 30, 2026, maintaining continuity in financial oversight and reinforcing confidence in the company’s reporting framework.
The most recent analyst rating on (ENTA) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
Spark’s Take on ENTA Stock
According to Spark, TipRanks’ AI Analyst, ENTA is a Neutral.
The score is held down primarily by weak financial performance: large ongoing losses and continued cash burn outweigh improved revenue momentum and a better leverage profile. Technicals are neutral-to-mixed (some trend support but soft momentum), while valuation is constrained by negative earnings and no dividend yield data.
To see Spark’s full report on ENTA stock, click here.
More about Enanta Pharmaceuticals
Enanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small-molecule drugs, with a portfolio centered on infectious diseases and liver-related conditions. The company’s work targets areas such as viral infections, leveraging its chemistry-driven approach to address significant unmet medical needs in specialized therapeutic markets.
Average Trading Volume: 265,306
Technical Sentiment Signal: Buy
Current Market Cap: $411.2M
For detailed information about ENTA stock, go to TipRanks’ Stock Analysis page.